Literature DB >> 33249444

Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines.

Alice Zhabokritsky1,2, Leah Szadkowski1,3, Curtis Cooper4,5, Mona Loutfy2,6, Alexander Wong7, Alison McClean8, Robert S Hogg8, Sharon L Walmsley1,2,9.   

Abstract

OBJECTIVES: To determine the time to CD4 : CD8 ratio normalization among Canadian adults living with HIV in the modern ART era. To identify characteristics associated with ratio normalization. PATIENTS AND METHODS: Retrospective analysis of the Canadian Observational Cohort (CANOC), an interprovincial cohort of ART-naive adults living with HIV, recruited from 11 treatment centres across Canada. We studied participants initiating ART between 1 January 2011 and 31 December 2016 with baseline CD4 : CD8 ratio <1.0 and ≥2 follow-up measurements. Normalization was defined as two consecutive CD4 : CD8 ratios ≥1.0. Kaplan-Meier estimates and log-rank tests described time to normalization. Univariable and multivariable proportional hazards (PH) models identified factors associated with ratio normalization.
RESULTS: Among 3218 participants, 909 (28%) normalized during a median 2.6 years of follow-up. Participants with higher baseline CD4+ T-cell count were more likely to achieve normalization; the probability of normalization by 5 years was 0.68 (95% CI 0.62-0.74) for those with baseline CD4+ T-cell count >500 cells/mm3 compared with 0.16 (95% CI 0.11-0.21) for those with ≤200 cells/mm3 (P < 0.0001). In a multivariable PH model, baseline CD4+ T-cell count was associated with a higher likelihood of achieving ratio normalization (adjusted HR = 1.5, 95% CI 1.5-1.6 per 100 cells/mm3, P < 0.0001). After adjusting for baseline characteristics, time-dependent ART class was not associated with ratio normalization.
CONCLUSIONS: Early ART initiation, at higher baseline CD4+ T-cell counts, has the greatest impact on CD4 : CD8 ratio normalization. Our study supports current treatment guidelines recommending immediate ART start, with no difference in ratio normalization observed based on ART class used.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33249444      PMCID: PMC7879150          DOI: 10.1093/jac/dkaa484

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery.

Authors:  S Serrano-Villar; S Moreno; M Fuentes-Ferrer; C Sánchez-Marcos; M Avila; T Sainz; N G P de Villar; A Fernández-Cruz; V Estrada
Journal:  HIV Med       Date:  2013-09-06       Impact factor: 3.180

2.  CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Authors:  Cristina Mussini; Patrizia Lorenzini; Alessandro Cozzi-Lepri; Giuseppe Lapadula; Giulia Marchetti; Emanuele Nicastri; Antonella Cingolani; Miriam Lichtner; Andrea Antinori; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Lancet HIV       Date:  2015-02-06       Impact factor: 12.767

3.  Premature age-related comorbidities among HIV-infected persons compared with the general population.

Authors:  Giovanni Guaraldi; Gabriella Orlando; Stefano Zona; Marianna Menozzi; Federica Carli; Elisa Garlassi; Alessandra Berti; Elisa Rossi; Alberto Roverato; Frank Palella
Journal:  Clin Infect Dis       Date:  2011-10-13       Impact factor: 9.079

4.  Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; JoAnn Kuruc; Cynthia Gay; Charles B Hicks; Kara S Mcgee; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

5.  The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age.

Authors:  Anders Wikby; Ingrid A Månsson; Boo Johansson; Jan Strindhall; Sven E Nilsson
Journal:  Biogerontology       Date:  2008-03-28       Impact factor: 4.277

6.  Human immunodeficiency virus and liver disease: An update.

Authors:  Kenneth E Sherman; Juergen Rockstroh; David Thomas
Journal:  Hepatology       Date:  2015-10-20       Impact factor: 17.425

7.  Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study.

Authors:  F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.

Authors:  Mar Masiá; Sergio Padilla; Xavier Barber; Marina Sanchis; Gertrudis Terol; Fernando Lidón; Félix Gutiérrez
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV.

Authors:  Win Min Han; Tanakorn Apornpong; Stephen J Kerr; Akarin Hiransuthikul; Sivaporn Gatechompol; Tanya Do; Kiat Ruxrungtham; Anchalee Avihingsanon
Journal:  AIDS Res Ther       Date:  2018-09-27       Impact factor: 2.250

10.  HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Authors:  Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823

View more
  1 in total

1.  Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial.

Authors:  Lifeng Wang; Zheng Zhang; Ruonan Xu; Xicheng Wang; Zhanjun Shu; Xiejie Chen; Siyu Wang; Jiaye Liu; Yuanyuan Li; Li Wang; Mi Zhang; Wei Yang; Ying Wang; Huihuang Huang; Bo Tu; Zhiwei Liang; Linghua Li; Jingxin Li; Yuying Hou; Ming Shi; Fu-Sheng Wang
Journal:  Signal Transduct Target Ther       Date:  2021-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.